<DOC>
	<DOCNO>NCT02445053</DOCNO>
	<brief_summary>To describe effectiveness KalydecoÂ® treatment patient cystic fibrosis ( CF ) 1 8 non G551D gate CFTR mutation ( G178R , S549N , S549R , G551S , G1244E , S1251N , S1255P , G1349D ) .</brief_summary>
	<brief_title>Observational Study Outcomes Cystic Fibrosis Patients With Selected Gating Mutations CFTR Allele ( The VOCAL Study )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female confirm diagnosis CF16 At least 1 allele 1 follow CFTR mutation : G178R , S549N , S549R , G551S , G1244E , S1251N , S1255P , G1349D Six year age old date sign ( Informed Consent Form ) ICF , appropriate , date assent Signed ICFs , appropriate , sign Assent Form Able understand study requirement comply study data collection procedures Previously expose Kalydeco , except currently treat patient start Kalydeco treatment within 6 month enrollment Currently enrol Kalydeco interventional study interventional therapeutic clinical study direct CFTR modulation History organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
</DOC>